clinical trial · NCT07169331
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
BeiGene·phase4·recruiting·n = 18
Waldenström's MacroglobulinemiaZanubrutinib
brief summary
The purpose of this study is to measure the efficacy and safety with zanubrutinib in adults with Treatment-Naive (TN) Waldenström Macroglobulinemia (WM). The main objective of this Phase 4 study is to further characterize the efficacy of zanubrutinib in Chinese participants with TN WM in order to fulfill the post-marketing requirements from the National Medical Products Administration (NMPA). Safety data will be collected and evaluated in this study as well.
started
Oct 17, 2025
primary completion
Oct 31, 2028
completion
Oct 31, 2028
last updated
Dec 19, 2025
official title
A Phase 4, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Patients With Treatment-Naive Waldenström Macroglobulinemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol